Validation of CHA2DS2 VASc Score Predictability of Stroke and Systemic Embolization in a Middle Eastern Population with AF: The Jordan Atrial Fibrillation (JoFib) Study

References

• Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042–1046. PMID: 15313941. doi:10.1161/01.CIR.0000140263.20897.42
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139:e56–e528. doi:10.1161/CIR.0000000000000659
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840–844. PMID: 8114238. doi:10.1001/jama.1994.03510350050036
   PubMed Web of Science ®Google Scholar
• Lee E, Choi EK, Han KD, et al. Mortality and causes of death in patients with atrial fibrillation: a nationwide population-based study. PLoS One. 2018;13(12):e0209687. PMID: 30586468; PMCID: PMC6306259. doi:10.1371/journal.pone.0209687
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263–272. doi:10.1378/chest.09-1584
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: the task force for the management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–2429. doi:10.1093/eurheartj/ehq278
   PubMed Web of Science ®Google Scholar
• van Doorn S, Debray TPA, Kaasenbrood F, et al. Predictive performance of the CHA2DS2-VASc rule in atrial fibrillation: a systematic review and meta-analysis. J Thromb Haemost. 2017;15:1065–1077. doi:10.1111/jth.13690
   PubMed Web of Science ®Google Scholar
• Sulzgruber P, Wassmann S, Semb AG, et al. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. Eur Heart J Cardiovasc Pharmacother. 2019;5:171–180. doi:10.1093/ehjcvp/pvz016
   PubMed Web of Science ®Google Scholar
• Chen YL, Cheng CL, Huang JL, et al.; TSOC-HFrEF Registry investigators and committee. Mortality prediction using CHADS2/CHA2DS2-VASc/R2CHADS2 scores in systolic heart failure patients with or without atrial fibrillation. Medicine. 2017;96(43):e8338. PMID: 29069008; PMCID: PMC5671841. doi:10.1097/MD.0000000000008338
   PubMed Web of Science ®Google Scholar
• Harb S, Hussein AAH, Saliba WIS, et al. P5142 Effect of anticoagulation on mortality by CHADSVASC score in patients with atrial fibrillation: comparison to patients without atrial fibrillation. Eur Heart J. 2018;39(suppl_1):15.
   PubMedGoogle Scholar
• Hammoudeh A, Khader Y, Tabbalat R, et al. One-year clinical outcome in middle Eastern patients with Atrial fibrillation: the Jordan Atrial fibrillation (JoFib) Study. Int J Vasc Med. 2022;2022:4240999. doi:10.1155/2022/4240999
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–2870. doi:10.1001/jama.285.22.2864
   PubMed Web of Science ®Google Scholar
• Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33:1500–1510. doi:10.1093/eurheartj/ehr488
   PubMed Web of Science ®Google Scholar
• Olesen JB, Gislason GH, Torp-Pedersen C, Lip GY. Atrial fibrillation and vascular disease--A bad combination. Clin Cardiol. 2012;35(Suppl1):15–20. PMID: 22246947; PMCID: PMC6652656. doi:10.1002/clc.20955
   PubMedGoogle Scholar
• Chen JY, Zhang AD, Lu HY, Guo J, Wang FF, Li ZC. CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis. J Geriatr Cardiol. 2013;10:258–266. doi:10.3969/j.issn.1671-5411.2013.03.004
   PubMed Web of Science ®Google Scholar
• Yu I, Song T-J, Kim BJ. CHADS2, CHA2DS2-VASc, ATRIA, and Essen stroke risk scores in stroke with atrial fibrillation. Medicine. 2021;100(3):e24000. doi:10.1097/MD.0000000000024000
   PubMed Web of Science ®Google Scholar
• Zhu WG, Xiong QM, Hong K. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation. Tex Heart Inst J. 2015;42(1):6–15. PMID: 25873792; PMCID: PMC4378047. doi:10.14503/THIJ-14-4353
   PubMedGoogle Scholar
• Oladiran O, Nwosu I. Stroke risk stratification in atrial fibrillation: a review of common risk factors. J Community Hosp Intern Med Perspect. 2019;9(2):113–120. PMID: 31044042; PMCID: PMC6484493. doi:10.1080/20009666.2019.1593781
   PubMed Web of Science ®Google Scholar
• Nielsen PB, Skjøth F, Overvad TF, Larsen TB, Lip GY. Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc? Circulation. 2018;137(8):832–840. doi:10.1161/CIRCULATIONAHA.117.029081
   PubMed Web of Science ®Google Scholar
• Mikkelsen AP, Lindhardsen J, Lip GY, Gislason GH, Torp-Pedersen C, Olesen JB. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J Thromb Haemost. 2012;10(9):1745–1751. PMID: 22805071. doi:10.1111/j.1538-7836.2012.04853.x
   PubMed Web of Science ®Google Scholar
• John Camm A, Savelieva I. Female gender as a risk factor for stroke associated with atrial fibrillation. Eur Heart J. 2017;38(19):1480–1484. doi:10.1093/eurheartj/ehx103
   PubMed Web of Science ®Google Scholar
• Wagstaff AJ, Overvad TF, Lip GYH, Lane DA. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. QJM. 2014;107(12):955–967. doi:10.1093/qjmed/hcu054
   PubMed Web of Science ®Google Scholar
• Waldo AL, Becker RC, Tapson VF, Colgan KJ; NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005;46(9):1729–1736. doi:10.1016/j.jacc.2005.06.077
   PubMed Web of Science ®Google Scholar
• Banerjee A, Lane DA, Torp-Pedersen C, Lip GYH. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, and apixaban) versus no treatment in a “real world” atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107:584–589. doi:10.1160/TH11-11-0784
   PubMed Web of Science ®Google Scholar
• Arboix A, Alió J. Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis. Curr Cardiol Rev. 2010;6(3):150–161. PMID: 21804774; PMCID: PMC2994107. doi:10.2174/157340310791658730
   PubMedGoogle Scholar
• Arboix A, Oliveres M, Massons J, Pujades R, García-Eroles L. Early differentiation of cardioembolic from atherothrombotic cerebral infarction: a multivariate analysis. Eur J Neurol. 1999;6:677–683. doi:10.1046/j.1468-1331.1999.660677.x
   PubMed Web of Science ®Google Scholar
• Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M. Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF general long-term registry. Europace. 2019;21(7):1013–1022. PMID: 30904925. doi:10.1093/europace/euz032
   PubMed Web of Science ®Google Scholar
• De Caterina R, Kim YH, Koretsune Y, et al. Safety and effectiveness of edoxaban in atrial fibrillation patients in routine clinical practice: one-year follow-up from the global noninterventional ETNA-AF program. J Clin Med. 2021;10(4):573. doi:10.3390/jcm10040573
   PubMed Web of Science ®Google Scholar